Mesoblast plans to file a BLA for Revascor by year-end after aligning with FDA on trial design, potency assays, and ...

Mesoblast Limited (NASDAQ:MESO) is one of the 7 Best ASX Stocks to Buy Now. The company announced that it received 7 years of ...

The graft versus host disease market is experiencing significant growth, driven by the ongoing adoption of branded therapies such as JAKAFI, IMBRUVICA, ORENCIA, and REZUROCK compared to off-label ...

Chronic graft-versus-host disease (GVHD) can inflict debilitating tissue injury and puts patients at high risk for death from infections. For several decades, little progress was made in the ...

Graft-versus-host disease is a condition that arises as a complication of stem cell transplant treatment, which is given for some types of cancer. Learn more.

Graft versus host disease, or GVHD, is a complication of a stem cell transplant, a treatment for blood cancers and certain blood or immune system disorders. With GVHD, white blood cells called T ...

Graft-versus-host disease is locally maintained in target tissues by resident progenitor-like T cells. Immunity , 2023; DOI: 10.1016/j.immuni.2023.01.003 Cite This Page : ...

Transfusion-associated graft-versus-host disease (TA-GVHD) is a rare and idiosyncratic complication following blood-product transfusion resulting from donor T cells reacting against patient skin ...

In rare cases, though, you may then develop a potentially serious condition called graft versus host disease (GvHD) because of the transplant. There are two kinds: chronic (cGvHD) and acute (aGvHD).